Silence Therapeutics PLC Save the Date: Capital Markets Event 14 November (7143O)
August 23 2017 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 7143O
Silence Therapeutics PLC
23 August 2017
Silence to host Capital Markets event on 14 November 2017
23 August 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that the Company will host a Capital
Markets event for investors, analysts and media at ME London Hotel,
Strand, London WC2R 1HA on Tuesday 14 November between 3:00pm and
5:30pm GMT.
At the meeting, Silence will provide an update on its RNAi
pipeline and proprietary technology platforms, as well as a review
of the Company's strategy. Further details will follow in due
course.
To register your interest, please contact
Abbas.Omaar@fticonsulting.com.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0) 20
FTI Consulting 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUGCRUPMGMP
(END) Dow Jones Newswires
August 23, 2017 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024